Oxybutynin Viatris (Oxybutynin Hydrochloride)

Oxybutynin hydrochloride, the active ingredient in Oxybutynin Viatris, is an antimuscarinic agent presented as a tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adults.

GNH USA supplies Oxybutynin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxybutynin Viatris is an antimuscarinic medication that acts on the urinary bladder smooth muscle to reduce involuntary contractions. - Overactive bladder: Improves bladder capacity and reduces urgency episodes. - Urge urinary incontinence: Decreases the frequency of leakage episodes. - Neurogenic bladder dysfunction: Helps control bladder spasms associated with neurological conditions.

Adverse reactions to oxybutynin are generally dose‑related and may vary in frequency.

Common Side Effects: - Dry mouth: Reduced salivary secretion leading to a feeling of dryness. - Constipation: Slowed gastrointestinal motility. - Blurred vision: Transient visual disturbances. - Drowsiness: Mild sedation or fatigue. - Urinary retention: Difficulty initiating or completing urination. - Heat intolerance: Reduced sweating causing discomfort in warm environments.

Serious or Rare Side Effects: - Severe allergic reaction: Rash, itching, swelling, or difficulty breathing. - Cardiac arrhythmia: Irregular heart rhythm requiring medical attention. - Acute glaucoma: Sudden eye pain with visual loss. - Hepatic dysfunction: Elevated liver enzymes or jaundice. - Persistent urinary retention: May require catheterisation. - Psychotic symptoms: Hallucinations or severe confusion.

Before prescribing oxybutynin, clinicians should evaluate patient-specific factors and monitor for adverse events. - Assess renal function: Adjust dosing in severe renal impairment. - Review cardiac history: Use caution in patients with known arrhythmias. - Evaluate glaucoma risk: Avoid in patients with narrow‑angle glaucoma. - Monitor for constipation: Provide dietary advice and laxatives if needed. - Check for urinary retention: Advise patients to report difficulty voiding. - Store at ambient temperature: Keep below 25°C in the original container, protected from moisture.

Oxybutynin may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticholinergic burden: Concurrent use with other strong anticholinergics increases risk of severe dry mouth, constipation and urinary retention. - CYP3A4 inhibitors: Strong inhibitors (e.g., ketoconazole) can raise oxybutynid plasma levels.

Moderate Interactions (Monitor Closely): - Antihistamines: May enhance anticholinergic side effects. - Tricyclic antidepressants: May increase sedation and urinary retention risk. - Opioids: Combined use can exacerbate constipation. - Beta‑blockers: May mask tachycardia caused by anticholinergic effects.